$2500 | Single User
$5000 | Site License
$7500 | Enterprise License

Pancreatic Cancer - Pipeline Review, H2 2018 [Report Updated: 21-12-2018]

Published by Global Markets Direct: 21 Dec 2018 | 228694 | In Stock

Introduction

Pancreatic Cancer - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H2 2018, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 20, 165, 153, 3, 8, 296, 39 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 20, 10, 2, 1, 56 and 8 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Pancreatic Cancer - Pipeline Review, H2 2018 [Report Updated: 21-12-2018]

  • Table of Contents

    Table of Contents 2

    Introduction 14

    Pancreatic Cancer - Overview 15

    Pancreatic Cancer - Therapeutics Development 16

    Pancreatic Cancer - Therapeutics Assessment 94

    Pancreatic Cancer - Companies Involved in Therapeutics Development 135

    Pancreatic Cancer - Drug Profiles 289

    Pancreatic Cancer - Dormant Projects 2665

    Pancreatic Cancer - Discontinued Products 2694

    Pancreatic Cancer - Product Development Milestones 2700

    Appendix 2711

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

228694 | GMDHC11023IDB

Number of Pages

2787

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Pancreatic Cancer Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Pancreatic Cancer Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Pancreatic Beta-Cell Protection - Hot Targets & Pipeline Analysis
“Pancreatic Beta-cell Protection Hot Targets & Pipeline Analysis” gives comprehensive insight on the...
12 Aug 2016 by IQ4I USD $3,600 More Info
Pancreatic Cancer Global Clinical Trials Review, H1, 2016
Pancreatic Cancer Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, ...
31 May 2016 by Global Data USD $2,500 More Info
Sunitinib Malate Market Forecast for Pancreatic Cancer, 2016-2017, G7 Countries, (U.S., Germany, France, U.K., Italy, Spain, Japan
The sunitinib malate market for pancreatic cancer is projected to reach USD 76.7 million by 2021, at...
19 May 2016 by MarketsandMarkets USD $4,650 More Info
Pancreatic Fistula Global Clinical Trials Review, H1, 2016
Pancreatic Fistula Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report,...
11 Mar 2016 by Global Data USD $2,500 More Info
Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape
Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds...
01 Dec 2015 by GBI Research USD $4,995 More Info
Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape
Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds...
01 Dec 2015 by GBI Research USD $4,995 More Info
Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation
Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class InnovationSummar...
01 Jun 2015 by GBI Research USD $6,995 More Info
Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation
Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class InnovationSummar...
01 Jun 2015 by GBI Research USD $6,995 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Pancreatic Cancer - Pipeline Review, H2 2018 [Report Updated: 21-12-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data